Verily moves into clinical trials
Verily, Alphabet’s unit focused on life sciences, announced yesterday it had formed “strategic alliances” with Novartis, Sanofi, Otsuka, and Pfizer to work on clinical trials. The overall goal is to reach more patients and to streamline the clinical trial process.
But what does that actually mean? And how will these alliances work?
Scarlet Shore, who leads Verily’s project Baseline, told STAT’s Matt Herper that much of what Verily brings to the table is based on what it has learned from its Baseline study, in which it collected six terabytes of data from 10,000 patients. But there are a handful of ways in which the company can leverage its advantages — by managing vast data sets, for instance, and improving trial recruitment through its connections to one of the most powerful forces in online advertising: Google.
Read more.
But what does that actually mean? And how will these alliances work?
Scarlet Shore, who leads Verily’s project Baseline, told STAT’s Matt Herper that much of what Verily brings to the table is based on what it has learned from its Baseline study, in which it collected six terabytes of data from 10,000 patients. But there are a handful of ways in which the company can leverage its advantages — by managing vast data sets, for instance, and improving trial recruitment through its connections to one of the most powerful forces in online advertising: Google.
Read more.
.png)
No hay comentarios:
Publicar un comentario